{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:09:53Z","timestamp":1790845793402,"version":"4.1.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamadermatol.2018.4556","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T15:35:49Z","timestamp":1547048149000},"page":"172","source":"Crossref","is-referenced-by-count":95,"title":["Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes"],"prefix":"10.1001","volume":"155","author":[{"given":"Seon Gu","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Dermatology, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9863","key":"doi180068r1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"1-2","key":"doi180068r2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid.","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"doi180068r3","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis.","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi180068r4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi180068r5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5021\/ad.2018.30.1.13","article-title":"Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea.","volume":"30","author":"Jeon","year":"2018","journal-title":"Ann Dermatol"},{"issue":"2","key":"doi180068r6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: lessons from autoimmune skin diseases.","volume":"110","author":"Chan","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi180068r7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"doi180068r8","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"doi180068r9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi180068r10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/ijd.2018.57.issue-7","article-title":"Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors: eight cases with clinical and immunological characterization.","volume":"57","author":"Garc\u00eda-D\u00edez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"doi180068r11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi180068r12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.2018.9.issue-2","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases.","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"7","key":"doi180068r13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study.","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"10","key":"doi180068r14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi180068r15","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.2018.32.issue-4","article-title":"Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade.","volume":"32","author":"Fania","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi180068r16","article-title":"Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors [published online March 23, 2018].","author":"Gravani","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi180068r17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","article-title":"Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients.","volume":"309","author":"Thorslund","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"doi180068r18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijd.2018.57.issue-1","article-title":"Ethnic variations in the epidemiology of bullous pemphigoid in Israel.","volume":"57","author":"Kridin","year":"2018","journal-title":"Int J Dermatol"},{"issue":"12","key":"doi180068r19","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany.","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi180068r20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"doi180068r21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jdv.2012.26.issue-2","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi180068r22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo.","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol"},{"key":"doi180068r23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2015.00387","article-title":"The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis.","volume":"6","author":"Waumans","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"doi180068r24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13300-013-0045-8","article-title":"Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.","volume":"4","author":"Tatosian","year":"2013","journal-title":"Diabetes Ther"},{"key":"doi180068r25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vascn.2014.11.002","article-title":"Establishment of a dipeptidyl peptidases (DPP) 8\/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.","volume":"71","author":"Huan","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"doi180068r26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nchembio.2229","article-title":"DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis.","volume":"13","author":"Okondo","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"2","key":"doi180068r27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","article-title":"Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid.","volume":"83","author":"Fang","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"6","key":"doi180068r28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study.","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2719752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T18:50:15Z","timestamp":1550083815000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.4556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4556","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}